In fact, LRRK2 inhibitors have been reported to rescue impairments in mitophagy [160] and reverse mtDNA damage observed in the immune cells of PD patients [161,162], indicating a role for mutation-induced LRRK2 activation in mitochondrial dysfunction and suggesting that mitochondrial deficits could be ameliorated by treatments using LRRK2 inhibitors, some of which are currently in clinical trials [163]. The gene discussed is LRRK2; the disease is Parkinson disease.